Altimmune Under Legal Scrutiny After Disappointing Pemvidutide Trial Results Impact Stock

Altimmune Faces Legal Scrutiny Amid Disappointing Trial Results

Altimmune, Inc., a clinical-stage biopharmaceutical company focused on therapies for obesity and liver diseases, is currently under investigation following a disappointing outcome from its IMPACT Phase 2b trial for Pemvidutide, targeting metabolic dysfunction-associated steatohepatitis (MASH). This inquiry is spearheaded by Berger Montague PC, which is assessing claims in light of a class action lawsuit filed after the trial results fell short of expectations. The trial's primary endpoint concerning fibrosis reduction did not achieve statistical significance, largely due to an unexpectedly high placebo response. Such results stand in stark contrast to prior projections from the company’s management, which had instilled optimism about the drug's efficacy.

Following the release of these trial results on June 26, 2025, Altimmune's stock price plunged over 53%, a dramatic drop from $7.71 to $3.61 within a single trading day. The sudden decrease not only raises concerns about the company’s future prospects but also prompts questions about the accuracy of the information disseminated to investors leading up to the trial's conclusion. With the substantial drop in stock price, investors who purchased Altimmune securities between August 10, 2023, and June 25, 2025, are encouraged to seek appointment as lead plaintiffs in the ongoing class action, with a deadline set for October 6, 2025.

The legal actions taken against Altimmune highlight the challenges facing clinical-stage biopharmaceutical companies, particularly in the competitive landscape of drug development. As Altimmune’s management acknowledges the limitations of the Phase 2 trial, they express hope for more favorable results in future Phase 3 studies. However, the current situation underscores the critical nature of transparent communication with investors, particularly during pivotal phases of clinical development. The ongoing investigations and lawsuits emphasize the need for companies in this sector to manage expectations carefully while ensuring that their communications are both accurate and honest.

In addition to Berger Montague, Levi & Korsinsky, LLP is also pursuing a class action lawsuit on behalf of affected investors. This firm, known for its significant achievements in securities litigation, alleges that Altimmune misled investors about the prospects of Pemvidutide. Both firms are reaching out to impacted investors, offering them an opportunity to discuss their rights and potential claims arising from the trial's disappointing results.

As Altimmune navigates this challenging period, the outcome of the legal proceedings may have lasting implications for the company's reputation and future endeavors, particularly as it seeks to advance its pipeline of innovative therapies in a demanding market.